R van Vollenhoven
Overview
Explore the profile of R van Vollenhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, Vollenhoven R, et al.
Arthritis Rheumatol
. 2018 Apr;
70(8):1256-1264.
PMID: 29671280
Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were...
2.
Emamikia S, Gentline C, Chatzidionysiou K, Arnaud L, Vollenhoven R
Scand J Rheumatol
. 2017 Sep;
47(2):131-140.
PMID: 28862513
Objective: The aim was to obtain a better understanding of the relationship between exposure to glucocorticoids (GCs) and adverse events (AEs) reported in a randomized controlled trial (RCT) in systemic...
3.
Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, et al.
Arthritis Care Res (Hoboken)
. 2017 Apr;
70(1):98-103.
PMID: 28388813
Objective: To determine the level of agreement of disease flare severity (distinguishing severe, moderate, and mild flare and persistent disease activity) in a large paper-patient exercise involving 988 individual cases...
4.
Emery P, Bingham 3rd C, Burmester G, Bykerk V, Furst D, Mariette X, et al.
Ann Rheum Dis
. 2016 Aug;
75(10):e69.
PMID: 27519773
No abstract available.
5.
Lourdudoss C, Elkan A, Hafstrom I, Jogestrand T, Gustafsson T, Vollenhoven R, et al.
Lupus
. 2016 Jun;
25(14):1602-1609.
PMID: 27334936
Objective: The aim of this study was to investigate the role of dietary micronutrient intake in systemic lupus erythematosus (SLE). Methods: This study included 111 SLE patients and 118 age...
6.
Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens J, Fautrel B, et al.
Ann Rheum Dis
. 2016 May;
76(1):126-132.
PMID: 27190098
Objective: To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis. Methods: In a discrete choice experiment,...
7.
Emery P, Bingham 3rd C, Burmester G, Bykerk V, Furst D, Mariette X, et al.
Ann Rheum Dis
. 2016 May;
76(1):96-104.
PMID: 27165179
Objectives: To assess the efficacy and safety of certolizumab pegol (CZP)+dose-optimised methotrexate (MTX) versus placebo (PBO)+dose-optimised MTX in inducing and sustaining clinical remission in DMARD-naïve patients with moderate-to-severe, active, progressive...
8.
Urowitz M, Gladman D, Anderson N, Su J, Romero-Diaz J, Bae S, et al.
Lupus Sci Med
. 2016 Apr;
3(1):e000143.
PMID: 27099765
Objective: To describe the frequency of myocardial infarction (MI) prior to the diagnosis of systemic lupus erythematosus (SLE) and within the first 2 years of follow-up. Methods: The systemic lupus...
9.
Bruce I, Urowitz M, Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al.
Lupus
. 2016 Mar;
25(7):699-709.
PMID: 26936891
Objective: To examine long-term organ damage and safety following treatment with belimumab plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE). Methods: Pooled data were examined from...
10.
Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, de Longueville M, Ralston P, et al.
RMD Open
. 2015 Oct;
1(1):e000044.
PMID: 26509064
Objectives: We report the incidence of tuberculosis (TB) across certolizumab pegol (CZP) clinical trials in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), before and after the...